Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
HER-2 Targeted Drugs for Breast Cancer market report explains the definition, types, applications, major countries, and major players of the HER-2 Targeted Drugs for Breast Cancer market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Pfizer
Beacon Pharmaceuticals Limited
Novartis
Hetero Drugs
CANbridge
GlaxoSmithKline
Chugai Pharmaceutical
Roche
Hengrui Medicine
Puma Biotechnology
By Type:
Trastuzumab
Pertuzumab
Lapatinib
Neratinib
Trastuzumab Emtansine
Pyrotinib
Other
By End-User:
Hospital
Clinic
Drug Center
Other
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global HER-2 Targeted Drugs for Breast Cancer Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 HER-2 Targeted Drugs for Breast Cancer Outlook to 2028- Original Forecasts
-
2.2 HER-2 Targeted Drugs for Breast Cancer Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term HER-2 Targeted Drugs for Breast Cancer Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global HER-2 Targeted Drugs for Breast Cancer Market- Recent Developments
-
6.1 HER-2 Targeted Drugs for Breast Cancer Market News and Developments
-
6.2 HER-2 Targeted Drugs for Breast Cancer Market Deals Landscape
7 HER-2 Targeted Drugs for Breast Cancer Raw Materials and Cost Structure Analysis
-
7.1 HER-2 Targeted Drugs for Breast Cancer Key Raw Materials
-
7.2 HER-2 Targeted Drugs for Breast Cancer Price Trend of Key Raw Materials
-
7.3 HER-2 Targeted Drugs for Breast Cancer Key Suppliers of Raw Materials
-
7.4 HER-2 Targeted Drugs for Breast Cancer Market Concentration Rate of Raw Materials
-
7.5 HER-2 Targeted Drugs for Breast Cancer Cost Structure Analysis
-
7.5.1 HER-2 Targeted Drugs for Breast Cancer Raw Materials Analysis
-
7.5.2 HER-2 Targeted Drugs for Breast Cancer Labor Cost Analysis
-
7.5.3 HER-2 Targeted Drugs for Breast Cancer Manufacturing Expenses Analysis
8 Global HER-2 Targeted Drugs for Breast Cancer Import and Export Analysis (Top 10 Countries)
-
8.1 Global HER-2 Targeted Drugs for Breast Cancer Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global HER-2 Targeted Drugs for Breast Cancer Export by Region (Top 10 Countries) (2017-2028)
9 Global HER-2 Targeted Drugs for Breast Cancer Market Outlook by Types and Applications to 2022
-
9.1 Global HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Trastuzumab Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Pertuzumab Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Lapatinib Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Neratinib Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Trastuzumab Emtansine Consumption and Growth Rate (2017-2022)
-
9.1.6 Global Pyrotinib Consumption and Growth Rate (2017-2022)
-
9.1.7 Global Other Consumption and Growth Rate (2017-2022)
-
9.2 Global HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinic Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Drug Center Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Other Consumption and Growth Rate (2017-2022)
10 Region and Country-wise HER-2 Targeted Drugs for Breast Cancer Market Analysis and Outlook till 2022
-
10.1 Global HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.2.2 Canada HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.2.3 Mexico HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.3.2 UK HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.3.3 Spain HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.3.4 Belgium HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.3.5 France HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.3.6 Italy HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.3.7 Denmark HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.3.8 Finland HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.3.9 Norway HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.3.10 Sweden HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.3.11 Poland HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.3.12 Russia HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.3.13 Turkey HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.4.2 Japan HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.4.3 India HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.4.4 South Korea HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.4.5 Pakistan HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.4.6 Bangladesh HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.4.7 Indonesia HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.4.8 Thailand HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.4.9 Singapore HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.4.10 Malaysia HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.4.11 Philippines HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.4.12 Vietnam HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.5.2 Colombia HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.5.3 Chile HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.5.4 Argentina HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.5.5 Venezuela HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.5.6 Peru HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.5.7 Puerto Rico HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.5.8 Ecuador HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.6.2 Kuwait HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.6.3 Oman HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.6.4 Qatar HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.6.5 Saudi Arabia HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.6.6 United Arab Emirates HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.7.2 South Africa HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.7.3 Egypt HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.7.4 Algeria HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
-
10.8.2 New Zealand HER-2 Targeted Drugs for Breast Cancer Consumption (2017-2022)
11 Global HER-2 Targeted Drugs for Breast Cancer Competitive Analysis
-
11.1 Pfizer
-
11.1.1 Pfizer Company Details
-
11.1.2 Pfizer HER-2 Targeted Drugs for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Pfizer HER-2 Targeted Drugs for Breast Cancer Main Business and Markets Served
-
11.1.4 Pfizer HER-2 Targeted Drugs for Breast Cancer Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Beacon Pharmaceuticals Limited
-
11.2.1 Beacon Pharmaceuticals Limited Company Details
-
11.2.2 Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Main Business and Markets Served
-
11.2.4 Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Novartis
-
11.3.1 Novartis Company Details
-
11.3.2 Novartis HER-2 Targeted Drugs for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Novartis HER-2 Targeted Drugs for Breast Cancer Main Business and Markets Served
-
11.3.4 Novartis HER-2 Targeted Drugs for Breast Cancer Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Hetero Drugs
-
11.4.1 Hetero Drugs Company Details
-
11.4.2 Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Main Business and Markets Served
-
11.4.4 Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 CANbridge
-
11.5.1 CANbridge Company Details
-
11.5.2 CANbridge HER-2 Targeted Drugs for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 CANbridge HER-2 Targeted Drugs for Breast Cancer Main Business and Markets Served
-
11.5.4 CANbridge HER-2 Targeted Drugs for Breast Cancer Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 GlaxoSmithKline
-
11.6.1 GlaxoSmithKline Company Details
-
11.6.2 GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Main Business and Markets Served
-
11.6.4 GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Chugai Pharmaceutical
-
11.7.1 Chugai Pharmaceutical Company Details
-
11.7.2 Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Main Business and Markets Served
-
11.7.4 Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Roche
-
11.8.1 Roche Company Details
-
11.8.2 Roche HER-2 Targeted Drugs for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Roche HER-2 Targeted Drugs for Breast Cancer Main Business and Markets Served
-
11.8.4 Roche HER-2 Targeted Drugs for Breast Cancer Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Hengrui Medicine
-
11.9.1 Hengrui Medicine Company Details
-
11.9.2 Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Main Business and Markets Served
-
11.9.4 Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Puma Biotechnology
-
11.10.1 Puma Biotechnology Company Details
-
11.10.2 Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Main Business and Markets Served
-
11.10.4 Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Product Portfolio
-
11.10.5 Recent Research and Development Strategies
12 Global HER-2 Targeted Drugs for Breast Cancer Market Outlook by Types and Applications to 2028
-
12.1 Global HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Trastuzumab Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Pertuzumab Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Lapatinib Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Neratinib Consumption Forecast and Growth Rate (2022-2028)
-
12.1.5 Global Trastuzumab Emtansine Consumption Forecast and Growth Rate (2022-2028)
-
12.1.6 Global Pyrotinib Consumption Forecast and Growth Rate (2022-2028)
-
12.1.7 Global Other Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Drug Center Consumption Forecast and Growth Rate (2022-2028)
-
12.2.4 Global Other Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise HER-2 Targeted Drugs for Breast Cancer Market Analysis and Outlook to 2028
-
13.1 Global HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.2.2 Canada HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.2.3 Mexico HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.3.2 UK HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.3.3 Spain HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.3.4 Belgium HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.3.5 France HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.3.6 Italy HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.3.7 Denmark HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.3.8 Finland HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.3.9 Norway HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.3.10 Sweden HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.3.11 Poland HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.3.12 Russia HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.3.13 Turkey HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.4.2 Japan HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.4.3 India HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.4.4 South Korea HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.4.5 Pakistan HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.4.7 Indonesia HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.4.8 Thailand HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.4.9 Singapore HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.4.10 Malaysia HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.4.11 Philippines HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.4.12 Vietnam HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.5.2 Colombia HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.5.3 Chile HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.5.4 Argentina HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.5.5 Venezuela HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.5.6 Peru HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.5.8 Ecuador HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.6.2 Kuwait HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.6.3 Oman HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.6.4 Qatar HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.7.2 South Africa HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.7.3 Egypt HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.7.4 Algeria HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
-
13.8.2 New Zealand HER-2 Targeted Drugs for Breast Cancer Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of HER-2 Targeted Drugs for Breast Cancer
-
Figure of HER-2 Targeted Drugs for Breast Cancer Picture
-
Table Global HER-2 Targeted Drugs for Breast Cancer Import by Region (Top 10 Countries) (2017-2028)
-
Table Global HER-2 Targeted Drugs for Breast Cancer Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Trastuzumab Consumption and Growth Rate (2017-2022)
-
Figure Global Pertuzumab Consumption and Growth Rate (2017-2022)
-
Figure Global Lapatinib Consumption and Growth Rate (2017-2022)
-
Figure Global Neratinib Consumption and Growth Rate (2017-2022)
-
Figure Global Trastuzumab Emtansine Consumption and Growth Rate (2017-2022)
-
Figure Global Pyrotinib Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Consumption and Growth Rate (2017-2022)
-
Figure Global Clinic Consumption and Growth Rate (2017-2022)
-
Figure Global Drug Center Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global HER-2 Targeted Drugs for Breast Cancer Consumption by Country (2017-2022)
-
Table North America HER-2 Targeted Drugs for Breast Cancer Consumption by Country (2017-2022)
-
Figure United States HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Canada HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Mexico HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Table Europe HER-2 Targeted Drugs for Breast Cancer Consumption by Country (2017-2022)
-
Figure Germany HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure UK HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Spain HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Belgium HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure France HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Italy HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Denmark HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Finland HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Norway HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Sweden HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Poland HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Russia HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Turkey HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Table APAC HER-2 Targeted Drugs for Breast Cancer Consumption by Country (2017-2022)
-
Figure China HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Japan HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure India HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure South Korea HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Pakistan HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Indonesia HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Thailand HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Singapore HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Malaysia HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Philippines HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Vietnam HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Table South America HER-2 Targeted Drugs for Breast Cancer Consumption by Country (2017-2022)
-
Figure Brazil HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Colombia HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Chile HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Argentina HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Venezuela HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Peru HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Ecuador HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Table GCC HER-2 Targeted Drugs for Breast Cancer Consumption by Country (2017-2022)
-
Figure Bahrain HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Kuwait HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Oman HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Qatar HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Table Africa HER-2 Targeted Drugs for Breast Cancer Consumption by Country (2017-2022)
-
Figure Nigeria HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure South Africa HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Egypt HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Algeria HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Table Oceania HER-2 Targeted Drugs for Breast Cancer Consumption by Country (2017-2022)
-
Figure Australia HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure New Zealand HER-2 Targeted Drugs for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Table Pfizer Company Details
-
Table Pfizer HER-2 Targeted Drugs for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer HER-2 Targeted Drugs for Breast Cancer Main Business and Markets Served
-
Table Pfizer HER-2 Targeted Drugs for Breast Cancer Product Portfolio
-
Table Beacon Pharmaceuticals Limited Company Details
-
Table Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Main Business and Markets Served
-
Table Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Product Portfolio
-
Table Novartis Company Details
-
Table Novartis HER-2 Targeted Drugs for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis HER-2 Targeted Drugs for Breast Cancer Main Business and Markets Served
-
Table Novartis HER-2 Targeted Drugs for Breast Cancer Product Portfolio
-
Table Hetero Drugs Company Details
-
Table Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Main Business and Markets Served
-
Table Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Product Portfolio
-
Table CANbridge Company Details
-
Table CANbridge HER-2 Targeted Drugs for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table CANbridge HER-2 Targeted Drugs for Breast Cancer Main Business and Markets Served
-
Table CANbridge HER-2 Targeted Drugs for Breast Cancer Product Portfolio
-
Table GlaxoSmithKline Company Details
-
Table GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Main Business and Markets Served
-
Table GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Product Portfolio
-
Table Chugai Pharmaceutical Company Details
-
Table Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Main Business and Markets Served
-
Table Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Product Portfolio
-
Table Roche Company Details
-
Table Roche HER-2 Targeted Drugs for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Roche HER-2 Targeted Drugs for Breast Cancer Main Business and Markets Served
-
Table Roche HER-2 Targeted Drugs for Breast Cancer Product Portfolio
-
Table Hengrui Medicine Company Details
-
Table Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Main Business and Markets Served
-
Table Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Product Portfolio
-
Table Puma Biotechnology Company Details
-
Table Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Main Business and Markets Served
-
Table Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Product Portfolio
-
Figure Global Trastuzumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Pertuzumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Lapatinib Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Neratinib Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Trastuzumab Emtansine Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Pyrotinib Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Drug Center Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global HER-2 Targeted Drugs for Breast Cancer Consumption Forecast by Country (2022-2028)
-
Table North America HER-2 Targeted Drugs for Breast Cancer Consumption Forecast by Country (2022-2028)
-
Figure United States HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe HER-2 Targeted Drugs for Breast Cancer Consumption Forecast by Country (2022-2028)
-
Figure Germany HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure France HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC HER-2 Targeted Drugs for Breast Cancer Consumption Forecast by Country (2022-2028)
-
Figure China HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure India HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Table South America HER-2 Targeted Drugs for Breast Cancer Consumption Forecast by Country (2022-2028)
-
Figure Brazil HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC HER-2 Targeted Drugs for Breast Cancer Consumption Forecast by Country (2022-2028)
-
Figure Bahrain HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa HER-2 Targeted Drugs for Breast Cancer Consumption Forecast by Country (2022-2028)
-
Figure Nigeria HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania HER-2 Targeted Drugs for Breast Cancer Consumption Forecast by Country (2022-2028)
-
Figure Australia HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand HER-2 Targeted Drugs for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
